Fosun Pharma (603173.SH) released its semi-annual performance report, with a net profit attributable to shareholders of 2.51 billion yuan, a year-on-year increase of 140.45%.

The Zhitong Finance APP reports that Fusda (603173.SH) has released its 2025 interim report. During the reporting period, the company achieved a revenue of 1.476 billion yuan, representing a year-on-year increase of 62.14%; the net profit attributable to shareholders was 0.251 billion yuan, a year-on-year increase of 140.45%; the net profit after deducting non-recurring gains and losses was 0.247 billion yuan, a year-on-year increase of 183.05%; the basic earnings per share was 1.59 yuan.